Stockscreener 앱 받기
6.90
1.29%
-0.09
시간 외 거래:
6.90
전일 마감가:
$6.99
열려 있는:
$7.06
하루 거래량:
115.21K
Relative Volume:
0.72
시가총액:
$147.50M
수익:
$66.59M
순이익/손실:
$-104.93M
주가수익비율:
-1.3939
EPS:
-4.95
순현금흐름:
$-96.48M
1주 성능:
-2.95%
1개월 성능:
-10.97%
6개월 성능:
+40.82%
1년 성능:
-48.85%
1일 변동 폭
$6.78
$7.06
1주일 범위
$6.78
$7.52
52주 변동 폭
$4.09
$13.49
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
4 KINGSBURY AVENUE, WATERTOWN, MA
ENTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
6.90 | 152.20M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
What technical models suggest about Enanta Pharmaceuticals Inc.’s comebackProfitable Trading Blueprint with Entry Zones - Newser
Is it too late to sell Enanta Pharmaceuticals Inc.Weekly Trend Watch with Market Signals - Newser
Will Enanta Pharmaceuticals Inc. price bounce be sustainableRisk-Managed Swing Setup and Signal Analysis - Newser
How Interest Rate Changes Impact Enanta Pharmaceuticals Inc. Stock PerformanceSummary of Reliable Long-Term Trade Models - Newser
Top chart patterns to watch in Enanta Pharmaceuticals Inc.Swing Entry Insight With Forecast Accuracy - Newser
Enanta Pharmaceuticals Inc. recovery potential after sell offSafe Entry Screening with Data Backed Analysis - Newser
Order flow analysis tools used on Enanta Pharmaceuticals Inc.Portfolio Review Summary with Five-Year Outlook - Newser
Has Enanta Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewShort-Term Stock Trend Forecast Guide - Newser
What makes Enanta Pharmaceuticals Inc. stock price move sharplyLow-Risk Reversal Pattern Analysis Tracker - Newser
Enanta ENTA 2025Q3 Earnings Preview Downside Ahead on Weak Revenue Projections - AInvest
Published on: 2025-08-08 18:39:38 - Newser
Detecting price anomalies in Enanta Pharmaceuticals Inc. with AIEarnings Impact and Stock Reaction Analysis - Newser
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration - Seeking Alpha
Enanta Pharmaceuticals Inc. Company Revenue and Profit Trends: A Deep DiveFree Trade Setups With Clear Risk Limits - Newser
Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series - BioSpace
Leading vs lagging indicators on Enanta Pharmaceuticals Inc. performanceMomentum Stocks with Breakout Potential - Newser
Enanta Pharmaceuticals to Participate in H.C. Wainwright & Co.'s Virtual Fireside Chat - AInvest
Can volume confirm reversal in Enanta Pharmaceuticals Inc.Free Consistent Profit Pattern Recognition Tools - Newser
Is Enanta Pharmaceuticals Inc. stock overvalued or undervaluedUnprecedented market success - Jammu Links News
How does Enanta Pharmaceuticals Inc. generate profit in a changing economyAchieve breakthrough gains with expert advice - Jammu Links News
How strong is Enanta Pharmaceuticals Inc. company’s balance sheetDiscover stocks with explosive growth potential - Jammu Links News
How does Enanta Pharmaceuticals Inc. compare to its industry peersAchieve impressive returns with smart timing - Jammu Links News
Is Enanta Pharmaceuticals Inc. a growth stock or a value stockAchieve remarkable returns with smart investing - Jammu Links News
What institutional investors are buying Enanta Pharmaceuticals Inc. stockBuild a diversified portfolio for maximum returns - Jammu Links News
How Enanta Pharmaceuticals Inc. stock performs during market volatilityStock Trading Session Highlights and Summary - Newser
Will Enanta Pharmaceuticals Inc. stock benefit from interest rate changesFree Alert Feed for Momentum Based Picks - Newser
Published on: 2025-08-01 16:58:16 - metal.it
What is the risk reward ratio of investing in Enanta Pharmaceuticals Inc. stockReal Time Planner For Fast Growth - Jammu Links News
How volatile is Enanta Pharmaceuticals Inc. stock compared to the marketEntry Signal Signals To Watch Now - jammulinksnews.com
Will Enanta Pharmaceuticals Inc. Stock Benefit from AI and Green Energy TrendsFree Target Return Focused Trade Insights - Newser
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):